ASH Highlights and Commentary: Chronic Lymphocytic Leukemia and Lymphomas
Year: 2021
Type: editorial
Abstract: Dr. Tinsley gives her perspective on encouraging results from the 5-year analysis of the MURANO study showing the benefit of fixed-duration venetoclax and rituximab. She evaluates early phase 1b/2 trial results showing the benefit of the ViPOR regimen but also associated adverse events that advanced practitioners (APs) should be aware of. Dr. Kurtin considers how APs can use the new Burkitt Lymphoma International Prognostic Index (BL-IPI) to discuss individual risk with patients and risk stratify them.
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3154260586